From: The safety, tolerability, pharmacokinetics, and pharmacodynamics of nebulized pegylated interferon α-2b in healthy adults: a randomized phase 1 trial
Treatment group 1 (n = 6)
Treatment group 2 (n = 6)
Control group (n = 6)
Cmax (ng/mL)
0.6183
4.333
0.7567
Tmax (h)
72
AUC (h·ng/mL)
40.3
328.6
63.95
AUC (h·nmol/L)
159
1298
253